NCT02062203View on ClinicalTrials.gov

Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Healthy Volunteers
Interventions
DRUG

AKB-6548 (therapeutic dose)

Single oral dose of AKB-6548 at a therapeutic dose level

DRUG

AKB-6548 (supratherapeutic dose)

Single oral dose of AKB-6548 at a supratherapeutic dose level

DRUG

Placebo

Single oral dose of placebo

DRUG

Moxifloxacin

Single oral dose of 400 mg moxifloxacin

Trial Locations (1)

Unknown

Evansville

Sponsors
All Listed Sponsors
lead

Akebia Therapeutics

INDUSTRY